ADAM22 and breast carcinoma: Tamoxifen-resistant LY2 wild-type (WT), LY2 ADAM22 overexpressing (LY2 ADAM22 KI) and ADAM22 CRISPR/Cas9 knock-out cells (LY2 ADAM22 KO) were injected into the mammary fat pad of the NOD/SCID mice to determine the effect of ADAM22 on breast cancer disease progression in vivo (Fig. 2a).